Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EBT (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed EBT for 5 consecutive years, with -$14.4 million as the latest value for Q4 2025.

  • Quarterly EBT rose 28.96% to -$14.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$55.3 million through Dec 2025, up 33.94% year-over-year, with the annual reading at -$54.7 million for FY2025, 34.72% up from the prior year.
  • EBT hit -$14.4 million in Q4 2025 for Kezar Life Sciences, down from -$10.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$10.7 million in Q3 2025 to a low of -$32.3 million in Q4 2023.
  • Historically, EBT has averaged -$18.2 million across 5 years, with a median of -$17.2 million in 2022.
  • Biggest five-year swings in EBT: plummeted 77.44% in 2023 and later skyrocketed 47.38% in 2025.
  • Year by year, EBT stood at -$14.2 million in 2021, then decreased by 27.93% to -$18.2 million in 2022, then tumbled by 77.44% to -$32.3 million in 2023, then skyrocketed by 37.33% to -$20.2 million in 2024, then grew by 28.96% to -$14.4 million in 2025.
  • Business Quant data shows EBT for KZR at -$14.4 million in Q4 2025, -$10.7 million in Q3 2025, and -$13.7 million in Q2 2025.